Outcomes4Me CAIHL draft report

Outcomes4Me: CAIHL reassessment

September 8, 2026. Published AI-assisted draft.

Outcomes4Me combines patient cancer education and trial discovery with a life-sciences business that offers sponsored content and recruitment. Commercial influence channels are documented. Their effect on actual treatment or trial rankings remains unverified.

Scope and agency posture

Patient cancer navigation and trial discovery, with a separately disclosed life-sciences business. The two sets of interests coexist.

Posture: Mixed, strong patient education with sponsor-funded routing caveats.

Axis: 62/100, retained provisionally. No numerical recalibration was performed.

Sources and documented findings

• The current life-sciences page sells precision marketing, sponsored education, lead generation and recruitment packets. Its example labels a prompt Sponsored. This establishes commercial influence channels, not evidence that treatment ranking is purchased. https://outcomes4me.com/for-life-sciences/

• The health policy permits health-data-based sponsored content, advertising and research use. It requires express authorization for name/contact sharing with research partners and describes consent for advertising-partner sharing, plus access, deletion and withdrawal requests. https://static.outcomes4me.com/health/

Patient authority

Inference from the documented workflow: The historical patient workflow lets people seek treatment information and trials. The current sponsor offering establishes a competing conversion objective, but does not demonstrate patients losing their final choice.

Critical capacity

Editorial assessment: Guideline-derived education in the baseline expands the questions a patient can ask. Sponsor labeling in one public example is useful, but does not verify in-app treatment or trial ordering.

Informed control

Editorial assessment: Secondary uses are expressly disclosed. The critical question is whether patients can recognize and decline commercial influence while retaining useful navigation, not simply who funds the service.

Assessment and limits

Mixed remains supported by a specific sponsor-content mechanism alongside patient education. Avoid turning a business-model concern into an unproven allegation of biased recommendations.

Confidence: Moderate for disclosed purposes and commercial offering.

Remaining uncertainty: Live sponsored labeling, ranking, diagnosis correction and retention after withdrawal remain unverified

Published documentation is evidence of stated conditions, not proof of actual implementation. Unknowns did not receive automatic negative points. Funding, sponsorship, and public code do not determine agency by themselves.

Review provenance

• Reviewer/model: OpenAI Codex / GPT-6.
• Method: Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
• Human review: Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
• Earlier review: 2026-06-10. Historical assessment. Earlier claims are not automatically reverified by this publication.